Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABLAGO: Conservative vs Ablative Treatment in Graves' Orbitopathy
NCT04776993Phase 3Recruiting
- Sponsor
- University of Pisa
- Start
- Mar 2023
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of methimazole in Graves' disease, sponsored by University of Pisa. Started Mar 2023; status: recruiting.
02
Drugs
methimazole
03
Conditions
Graves' disease
Beyond the preview
Go deeper on NCT04776993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04776993.